Valuation: NanoGroup S.A.

Market Cap 100M 25.47M 22.81M 21.05M 19.05M 35.62M 2.43B 36.19M 251M 1.27B 95.59M 93.56M 4.02B P/E 2024
-18x
P/E 2025 -9.21x
Enterprise Value 84.72M 21.54M 19.29M 17.8M 16.11M 30.12M 2.05B 30.61M 212M 1.07B 80.84M 79.12M 3.4B EV / Sales 2024
35,113x
EV / Sales 2025 -
Free-Float
68.64%
Yield 2024 *
-
Yield 2025 -
1 day+2.16%
1 week+0.85%
Current month-4.84%
1 month-4.84%
3 months-5.60%
6 months-3.87%
Current year-10.94%
1 week 2.28
Extreme 2.275
2.38
1 month 2.22
Extreme 2.225
2.5
Current year 2.18
Extreme 2.175
2.88
1 year 2.18
Extreme 2.175
3.2
3 years 0.85
Extreme 0.85
4.37
5 years 0.85
Extreme 0.85
5.17
10 years 0.85
Extreme 0.85
13
Manager TitleAgeSince
Chief Executive Officer 50 2022-11-30
Corporate Officer/Principal 61 2024-06-28
Corporate Officer/Principal 59 2024-06-28
Director TitleAgeSince
Chairman 58 2016-10-16
Director/Board Member 75 2021-06-27
Director/Board Member 57 2017-04-18
Change 5-day change 1-year change 3-year change Capi.($)
+2.16%+0.85%-5.60%+143.30% 25.41M
+0.34%+1.12%+34.75%+61.06% 64.14B
+0.98%+2.68%+12.25%+82.98% 55.53B
+1.75%+2.01%+13.30%+103.69% 53.03B
-1.43%-1.17%+26.27%+52.86% 45.99B
-0.48%-2.80%+18.01%+117.99% 42.45B
+0.82%+1.37%+227.94%+922.41% 40.45B
-0.26%-2.57%+12.55%+45.18% 32.25B
-2.07%+42.73%+103.77%+88.74% 34.47B
-2.72%-0.44%+22.58%-5.63% 24.23B
Average -0.09%+3.38%+46.58%+161.26% 39.26B
Weighted average by Cap. -0.08%+3.13%+49.26%+160.88%

Financials

2024 2025
Net sales 2.1K 533.94 478.25 441.22 399.27 746.61 50.85K 758.68 5.26K 26.61K 2K 1.96K 84.28K -
Net income -5.17M -1.31M -1.18M -1.09M -983K -1.84M -125M -1.87M -12.95M -65.48M -4.93M -4.83M -207M -9.45M -2.4M -2.15M -1.98M -1.8M -3.36M -229M -3.41M -23.68M -120M -9.01M -8.82M -379M
Net Debt -7.83M -1.99M -1.78M -1.64M -1.49M -2.78M -190M -2.83M -19.62M -99.21M -7.47M -7.31M -314M -15.46M -3.93M -3.52M -3.25M -2.94M -5.5M -374M -5.58M -38.74M -196M -14.75M -14.44M -620M
Projected Income Statement - Annual - NanoGroup S.A.
Logo NanoGroup S.A.
Nanogroup SA is a Poland-based company engaged in the biotechnology sector. The Company focuses on the investment in, as well as development of advanced biotechnological projects in the areas of cancer prevention, early diagnosis, targeted cancer therapies and ontological rehabilitation. Its projects portfolio includes NanoVelos, which is responsible for the creation of drug delivery system for proven oncologic medicines to optimize their performance; NanoSanguis, which develops artificial blood to keep alive patients wounded in accidents, as well as a system, named Organ farm, to preserve human organs ex vivo, and NanoThea, which is dedicated to technology that detects cancer cells in early stage.
Employees
-
Date Price Change Volume
26-10-29 PLN 2.350 -0.21% 10,026
26-10-28 PLN 2.355 +1.95% 6,855
26-10-27 PLN 2.310 0.00% 7,010
26-10-26 PLN 2.310 -0.86% 8,572
26-10-23 PLN 2.330 -0.43% 18,586